Luke Lemke, MD
Family Medicine · Columbus, NENPI 1104820489
Payments from drug & device makers
Across 123 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$360
- Novo Nordisk$284
- AbbVie$280
- Amgen$191
- Lilly USA, LLC$152
- Pfizer$114
- plus $604 from 17 others
What the payments were for
- Food & beverage$1,87995%
- Education$1065%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $360 |
| Novo Nordisk | 20 | $284 |
| AbbVie(2 entities) | 30 | $280 |
| Amgen | 11 | $191 |
| Lilly USA, LLC | 10 | $152 |
| Pfizer | 8 | $114 |
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| Boehringer Ingelheim | 6 | $87 |
| Abbott | 3 | $60 |
| GSK | 3 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Baxter Healthcare | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Johnson & Johnson(2 entities) | 2 | $28 |
| Novartis | 1 | $27 |
| Merck | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Medicure Pharma Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$1,984 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 307 | $240,400 |
| EliquisApixaban | 293 | $198,167 |
| MounjaroTirzepatide | 115 | $129,219 |
| OzempicSemaglutide | 119 | $117,169 |
| FarxigaDapagliflozin Propanediol | 153 | $96,216 |
| HumiraAdalimumab | 13 | $88,550 |
| TrulicityDulaglutide | 71 | $78,407 |
| XareltoRivaroxaban | 67 | $46,775 |
| MyrbetriqMirabegron | 98 | $43,796 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $34,071 |
| Repatha SureclickEvolocumab | 38 | $33,071 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $28,107 |
| JanuviaSitagliptin Phosphate | 34 | $23,957 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $23,333 |
| Praluent PenAlirocumab | 35 | $17,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $87 | $250,991321 claims |
| Lilly USA, LLCMounjaro, Trulicity | $152 | $207,626186 claims |
| PfizerEliquis | $114 | $198,167293 claims |
| Novo NordiskOzempic, Levemir | $284 | $121,218145 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $360 | $108,188166 claims |
| AbbVieHumira, Linzess, Synthroid | $280 | $101,463115 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $42 | $57,156120 claims |
| Johnson & JohnsonXarelto | $28 | $46,77567 claims |
| MerckJanuvia | $26 | $23,95734 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $13 | $7,70426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Columbus
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.